Global TarGeT study expands to Australia, marking a major milestone in brain cancer research

In partnership with ANZCHOG and fthe TarGeT Collaborative, we are thrilled to announce that Target D of the TarGeT umbrella trial is now officially activated at Sydney Children’s Hospital!

This marks a massive milestone: Sydney is the very first international site to open outside the US. This arm of the study assesses the efficacy of olutasidenib and temozolomide for patients with IDH1-mutant, newly-diagnosed High-Grade Glioma (HGG) and Diffuse Intrinsic Pontine Glioma (DIPG).

Beyond the clinical trial, teams are diving deep into correlative studies, exploring everything from neuroimaging and pseudoprogression to patient-reported outcomes.

Proud to be part of this collaboration alongside Children's Cancer Foundation (Australia), My Room Children’s Cancer Charity, The Kids'​ Cancer Project, Mark Hughes Foundation Beanie for Brain Cancer, The Cure Starts Now Cancer Foundation

To learn more, visit: ANZCHOG